Open Site Navigation
Intertrade Ireland Seedcorn Regional Finalists 2021
SEPTEMBER 2020

Intertrade Ireland Seedcorn Regional Finalists 2021

VascVersa reach regional finals in Intertrade Ireland Seedcorn Competition 2021. This Seedcorn investor readiness competition was a fantastic opportunity for the company to secure expert feedback...

Vascversa participated in 2021 Pulse event
MARCH 2021

Vascversa participated in 2021 Pulse event

VascVersa were awarded a place on a prestigious PULSE programme. This was a three-day leadership and entrepreneurship training programme developed by the BIA and the Francis Crick Institute.

NI’s First Cell Therapy Company Secure Six Figure Deal
APRIL 2021

NI’s First Cell Therapy Company Secure Six Figure Deal

Award winning Queen’s University spin out VascVersa has completed a six-figure deal in its first investment round led by QUBIS, with support from Co-Fund NI and a group of angel investors from...

VascVersa attend Cell & Gene at the Abbey conference, Galway
NOVEMBER 2021

VascVersa attend Cell & Gene at the Abbey conference, Galway

VascVersa were excited to attend their first face to face event in 2021 at the beautiful Glenlo Abbey in Galway. This event hosted by HiTech Health was a three-day event featuring international experts...

VascVersa join the NA-ATCC
DECEMBER 2021

VascVersa join the NA-ATCC

VascVersa were delighted to become an NA-ATCC partner. The consortium consists of twenty industry, NHS and academic organisations lead by...

Successful Biomedical Catalyst Funding Award
FEBRUARY 2022

Successful Biomedical Catalyst Funding Award

VascVersa leads consortium to advance new cell therapy for the treatment of chronic non-healing wounds.

VascVersa Pitched at HBAN Ulster Investor Meeting
MARCH 2022

VascVersa Pitched at HBAN Ulster Investor Meeting

This face to face event supported by Clarendon Fund Managers provided a fantastic opportunity for the team to showcase ANGICYTE™ technology to a local investor network. VascVersa presented...

VascVersa proudly working with Anthony Nolan charity
MARCH 2022

VascVersa proudly working with Anthony Nolan charity

VascVersa will work with Anthony Nolan Cell & Gene Therapy Services who will support the company by supplying high-quality cord material for VascVersa to facilitate their development of ANGICYTE™ technology.

VascVersa completes second investment round
AUGUST 2022

VascVersa completes second investment round

VascVersa completes second investment round to accelerate development of ground-breaking cell therapies.

News